Dong Jinpei, Teng Guigen, Wei Tiantong, Gao Wen, Wang Huahong
Department of Gastroenterology, Peking University First Hospital, Peking University, Beijing, China.
PLoS One. 2016 Dec 22;11(12):e0168785. doi: 10.1371/journal.pone.0168785. eCollection 2016.
Probiotics are widely used for the induction and maintenance of remission in inflammatory bowel disease (IBD) and pouchitis. There are a large number of meta-analyses (MAs)/ systematic reviews (SRs) on this subject, the methodological quality of which has not been evaluated.
This study aimed to evaluate the methodological quality of and summarize the evidence obtained from MAs/SRs of probiotic treatments for IBD and pouchitis patients.
The PubMed, EMBASE, Cochrane Library and China National Knowledge Infrastructure (CNKI) databases were searched to identify Chinese and English language MAs/SRs of the use of probiotics for IBD and pouchitis. The Assessment of Multiple Systematic Reviews (AMSTAR) scale was used to assess the methodological quality of the studies.
A total of 36 MAs/SRs were evaluated. The AMSTAR scores of the included studies ranged from 1 to 10, and the average score was 5.81. According to the Canadian Agency for Drugs and Technologies in Health, 4 articles were classified as high quality, 24 articles were classified as moderate quality, and 8 articles were classified as low quality. Most of the MAs/SRs suggested that probiotics had potential benefits for patients with ulcerative colitis (UC), but failed to show effectiveness in the induction and maintenance of remission in Crohn's disease (CD). The probiotic preparation VSL#3 may play a beneficial role in pouchitis.
The overall methodological quality of the current MAs/SRs in the field of probiotics for IBD and pouchitis was found to be low to moderate. More MAs/SRs of high quality are required to support using probiotics to treat IBD and pouchitis.
益生菌被广泛用于诱导和维持炎症性肠病（IBD）和袋炎的缓解。关于这一主题有大量的荟萃分析（MAs）/系统评价（SRs），但其方法学质量尚未得到评估。
本研究旨在评估益生菌治疗IBD和袋炎患者的MAs/SRs的方法学质量，并总结从中获得的证据。
检索PubMed、EMBASE、Cochrane图书馆和中国知网（CNKI）数据库，以识别关于益生菌用于IBD和袋炎的中文和英文MAs/SRs。使用多系统评价评估（AMSTAR）量表来评估研究的方法学质量。
共评估了36项MAs/SRs。纳入研究的AMSTAR评分范围为1至10，平均评分为5.81。根据加拿大卫生技术评估局的标准，4篇文章被归类为高质量，24篇文章被归类为中等质量，8篇文章被归类为低质量。大多数MAs/SRs表明，益生菌对溃疡性结肠炎（UC）患者有潜在益处，但在诱导和维持克罗恩病（CD）缓解方面未显示出有效性。益生菌制剂VSL#3可能在袋炎中发挥有益作用。
目前关于益生菌用于IBD和袋炎领域的MAs/SRs的总体方法学质量被发现为低到中等。需要更多高质量的MAs/SRs来支持使用益生菌治疗IBD和袋炎。
